Financhill
Sell
28

SRRK Quote, Financials, Valuation and Earnings

Last price:
$34.55
Seasonality move :
-30.93%
Day range:
$34.53 - $36.34
52-week range:
$6.76 - $46.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
73.03x
P/B ratio:
8.89x
Volume:
1.1M
Avg. volume:
834.5K
1-year change:
134.1%
Market cap:
$3.3B
Revenue:
--
EPS (TTM):
-$2.46

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SRRK
Scholar Rock Holding
-- -$0.63 -- -19.94% $50.50
GILD
Gilead Sciences
$7.2B $1.70 1.18% 49.16% $111.26
LLY
Eli Lilly and
$13.4B $5.07 45.75% 89.16% $1,006.63
MRK
Merck &
$15.5B $1.67 -1.15% 13.5% $112.29
TERN
Terns Pharmaceuticals
-- -$0.30 -- -7.38% $19.06
VKTX
Viking Therapeutics
-- -$0.27 -- -21.87% $99.29
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SRRK
Scholar Rock Holding
$34.60 $50.50 $3.3B -- $0.00 0% 73.03x
GILD
Gilead Sciences
$111.44 $111.26 $138.8B 301.19x $0.79 2.78% 4.87x
LLY
Eli Lilly and
$813.48 $1,006.63 $730.6B 69.47x $1.50 0.66% 16.33x
MRK
Merck &
$94.57 $112.29 $238.9B 14.05x $0.81 3.3% 3.74x
TERN
Terns Pharmaceuticals
$3.18 $19.06 $269.7M -- $0.00 0% --
VKTX
Viking Therapeutics
$30.89 $99.29 $3.5B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SRRK
Scholar Rock Holding
-- -4.868 -- --
GILD
Gilead Sciences
58.02% 0.435 23.22% 1.33x
LLY
Eli Lilly and
70.33% 0.371 5.05% 0.59x
MRK
Merck &
44.49% 0.543 15.58% 0.84x
TERN
Terns Pharmaceuticals
-- 2.694 -- --
VKTX
Viking Therapeutics
-- -1.225 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SRRK
Scholar Rock Holding
-- -$69.4M -- -- -- -$49.5M
GILD
Gilead Sciences
$6B $2.4B 1.09% 2.5% 31.92% $2.8B
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M
MRK
Merck &
$11.8B $4.3B 21.67% 40.25% 28.79% $2.5B
TERN
Terns Pharmaceuticals
-- -$24.9M -- -- -- -$16.5M
VKTX
Viking Therapeutics
-- -$46.2M -- -- -- -$31.2M

Scholar Rock Holding vs. Competitors

  • Which has Higher Returns SRRK or GILD?

    Gilead Sciences has a net margin of -- compared to Scholar Rock Holding's net margin of 23.56%. Scholar Rock Holding's return on equity of -- beat Gilead Sciences's return on equity of 2.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRRK
    Scholar Rock Holding
    -- -$0.61 --
    GILD
    Gilead Sciences
    79.11% $1.42 $46B
  • What do Analysts Say About SRRK or GILD?

    Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 45.95%. On the other hand Gilead Sciences has an analysts' consensus of $111.26 which suggests that it could fall by -0.16%. Given that Scholar Rock Holding has higher upside potential than Gilead Sciences, analysts believe Scholar Rock Holding is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRRK
    Scholar Rock Holding
    5 0 0
    GILD
    Gilead Sciences
    15 11 0
  • Is SRRK or GILD More Risky?

    Scholar Rock Holding has a beta of 0.592, which suggesting that the stock is 40.765% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

  • Which is a Better Dividend Stock SRRK or GILD?

    Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.78% to investors and pays a quarterly dividend of $0.79 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

  • Which has Better Financial Ratios SRRK or GILD?

    Scholar Rock Holding quarterly revenues are --, which are smaller than Gilead Sciences quarterly revenues of $7.6B. Scholar Rock Holding's net income of -$66.5M is lower than Gilead Sciences's net income of $1.8B. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 301.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 73.03x versus 4.87x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRRK
    Scholar Rock Holding
    73.03x -- -- -$66.5M
    GILD
    Gilead Sciences
    4.87x 301.19x $7.6B $1.8B
  • Which has Higher Returns SRRK or LLY?

    Eli Lilly and has a net margin of -- compared to Scholar Rock Holding's net margin of 32.59%. Scholar Rock Holding's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRRK
    Scholar Rock Holding
    -- -$0.61 --
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About SRRK or LLY?

    Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 45.95%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Scholar Rock Holding has higher upside potential than Eli Lilly and, analysts believe Scholar Rock Holding is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRRK
    Scholar Rock Holding
    5 0 0
    LLY
    Eli Lilly and
    16 4 0
  • Is SRRK or LLY More Risky?

    Scholar Rock Holding has a beta of 0.592, which suggesting that the stock is 40.765% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

  • Which is a Better Dividend Stock SRRK or LLY?

    Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SRRK or LLY?

    Scholar Rock Holding quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Scholar Rock Holding's net income of -$66.5M is lower than Eli Lilly and's net income of $4.4B. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 73.03x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRRK
    Scholar Rock Holding
    73.03x -- -- -$66.5M
    LLY
    Eli Lilly and
    16.33x 69.47x $13.5B $4.4B
  • Which has Higher Returns SRRK or MRK?

    Merck & has a net margin of -- compared to Scholar Rock Holding's net margin of 23.96%. Scholar Rock Holding's return on equity of -- beat Merck &'s return on equity of 40.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    SRRK
    Scholar Rock Holding
    -- -$0.61 --
    MRK
    Merck &
    75.5% $1.48 $83.5B
  • What do Analysts Say About SRRK or MRK?

    Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 45.95%. On the other hand Merck & has an analysts' consensus of $112.29 which suggests that it could grow by 18.73%. Given that Scholar Rock Holding has higher upside potential than Merck &, analysts believe Scholar Rock Holding is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRRK
    Scholar Rock Holding
    5 0 0
    MRK
    Merck &
    11 10 0
  • Is SRRK or MRK More Risky?

    Scholar Rock Holding has a beta of 0.592, which suggesting that the stock is 40.765% less volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.

  • Which is a Better Dividend Stock SRRK or MRK?

    Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.3% to investors and pays a quarterly dividend of $0.81 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios SRRK or MRK?

    Scholar Rock Holding quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.6B. Scholar Rock Holding's net income of -$66.5M is lower than Merck &'s net income of $3.7B. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Merck &'s PE ratio is 14.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 73.03x versus 3.74x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRRK
    Scholar Rock Holding
    73.03x -- -- -$66.5M
    MRK
    Merck &
    3.74x 14.05x $15.6B $3.7B
  • Which has Higher Returns SRRK or TERN?

    Terns Pharmaceuticals has a net margin of -- compared to Scholar Rock Holding's net margin of --. Scholar Rock Holding's return on equity of -- beat Terns Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SRRK
    Scholar Rock Holding
    -- -$0.61 --
    TERN
    Terns Pharmaceuticals
    -- -$0.28 --
  • What do Analysts Say About SRRK or TERN?

    Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 45.95%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.06 which suggests that it could grow by 500.39%. Given that Terns Pharmaceuticals has higher upside potential than Scholar Rock Holding, analysts believe Terns Pharmaceuticals is more attractive than Scholar Rock Holding.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRRK
    Scholar Rock Holding
    5 0 0
    TERN
    Terns Pharmaceuticals
    5 3 0
  • Is SRRK or TERN More Risky?

    Scholar Rock Holding has a beta of 0.592, which suggesting that the stock is 40.765% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock SRRK or TERN?

    Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRRK or TERN?

    Scholar Rock Holding quarterly revenues are --, which are smaller than Terns Pharmaceuticals quarterly revenues of --. Scholar Rock Holding's net income of -$66.5M is lower than Terns Pharmaceuticals's net income of -$21.9M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 73.03x versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRRK
    Scholar Rock Holding
    73.03x -- -- -$66.5M
    TERN
    Terns Pharmaceuticals
    -- -- -- -$21.9M
  • Which has Higher Returns SRRK or VKTX?

    Viking Therapeutics has a net margin of -- compared to Scholar Rock Holding's net margin of --. Scholar Rock Holding's return on equity of -- beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SRRK
    Scholar Rock Holding
    -- -$0.61 --
    VKTX
    Viking Therapeutics
    -- -$0.32 --
  • What do Analysts Say About SRRK or VKTX?

    Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 45.95%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 221.44%. Given that Viking Therapeutics has higher upside potential than Scholar Rock Holding, analysts believe Viking Therapeutics is more attractive than Scholar Rock Holding.

    Company Buy Ratings Hold Ratings Sell Ratings
    SRRK
    Scholar Rock Holding
    5 0 0
    VKTX
    Viking Therapeutics
    9 1 0
  • Is SRRK or VKTX More Risky?

    Scholar Rock Holding has a beta of 0.592, which suggesting that the stock is 40.765% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

  • Which is a Better Dividend Stock SRRK or VKTX?

    Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SRRK or VKTX?

    Scholar Rock Holding quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Scholar Rock Holding's net income of -$66.5M is lower than Viking Therapeutics's net income of -$35.4M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 73.03x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SRRK
    Scholar Rock Holding
    73.03x -- -- -$66.5M
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock